Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Non-hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT00005786
What this trial is testing

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaProlymphocytic Leukemia+8 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Looking for participantsNCT07365306
What this trial is testing

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Mediastinal Large B-Cell Lymphoma+5 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT06238648
What this trial is testing

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United 120
Testing effectiveness (Phase 2)Study completedNCT03105336
What this trial is testing

Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin Lymphoma
Kite, A Gilead Company 159
Early research (Phase 1)Study completedNCT03985189
What this trial is testing

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. 14
Testing effectiveness (Phase 2)UnknownNCT05543070
What this trial is testing

Low-dose Radiotherapy in iNHL

Who this might be right for
Indolent LymphomaLow-dose Radiotherapy
Chinese Academy of Medical Sciences 73
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT03520920
What this trial is testing

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Who this might be right for
Marginal Zone LymphomaFollicular LymphomaDiffuse Large B-Cell Lymphoma
BeiGene 41
Testing effectiveness (Phase 2)Study completedNCT04038359
What this trial is testing

Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Indolent Non-Hodgkin Lymphoma
SecuraBio 103
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Testing effectiveness (Phase 2)Looking for participantsNCT04669171
What this trial is testing

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone Lymphoma
Enterome 80
Testing effectiveness (Phase 2)Study completedNCT00547534
What this trial is testing

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
University of Rochester 31
Testing effectiveness (Phase 2)Ended earlyNCT05265975
What this trial is testing

ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-Hodgkin Lymphoma
Antengene Corporation 54
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Early research (Phase 1)WithdrawnNCT04372641
What this trial is testing

Testing the Safety of CB-5339 in Patients With Cancer

Who this might be right for
Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaLocally Advanced Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT00577993
What this trial is testing

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 210
Testing effectiveness (Phase 2)Looking for participantsNCT06784726
What this trial is testing

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
University of Washington 27
Testing effectiveness (Phase 2)WithdrawnNCT02653989
What this trial is testing

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Lymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma
Medivation, Inc.
Testing effectiveness (Phase 2)Study completedNCT00086034
What this trial is testing

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaNon-Hodgkin's Lymphoma
Pharmacyclics LLC. 35
Next Page
43